Drug screening of rhodanine derivatives for antibacterial activity

Suresh Maddila,Sridevi Gorle,Sreekantha B Jonnalagadda
DOI: https://doi.org/10.1080/17460441.2020.1696768
2019-11-28
Expert Opinion on Drug Discovery
Abstract:<span><b>Introduction</b>: Bacteriological infections are a major risk to human health. These include all hospital and public-acquired infections. In drug discovery, rhodanines are privileged heterocyclic frameworks. Their derivatives possess strong anti-bacterial activity and some of them have shown potent activity against multidrug-resistant pathogens, both under <i>in vitro</i> and <i>in vivo</i> conditions. To treat multi-drug resistant pathogens, the development of novel potent drugs, with superior anti-bacterial efficacy, is paramount. One avenue which shows promise is the design and development of novel rhodanines.<b>Areas covered</b>: This review summarizes the status on rhodanine-based derivatives and their anti-bacterial activity, based on published research over the past six years. Furthermore, to facilitate the design of novel derivatives with improved functions, their structure–activity relationships are assessed with reference to their efficacy as anti-bacterial agents and their toxicity.<b>Expert opinion</b>: The pharmacological activity of molecules bearing a rhodanine scaffold needs to be very critically assessed in spite of considerable information available from various biological evaluations. Although, some data on structure–activity relationship frameworks is available, information is not adequate to optimize the efficacy of rhodanine derivatives for different applications.</span>
pharmacology & pharmacy
What problem does this paper attempt to address?